The white plague is a historical name for tuberculosis, one of the deadliest infectious diseases in human history. The nickname was coined in the 18th century because of the extreme anemic pallor that marked people suffering from the disease. While other plagues left victims covered in dark sores or swelling, tuberculosis drained the color from a person’s skin, making them look ghostly white as the infection slowly consumed their body from the inside.
Why It Was Called the White Plague
Tuberculosis earned several names over the centuries. The ancient Greeks called it “phthisis,” meaning wasting or consumption, because patients visibly wasted away. By the 1700s, the disease was killing so many people across Europe that it earned the more dramatic label “white plague,” a direct reference to the stark pallor of its victims. The name also served as a contrast to the Black Death (bubonic plague), which had devastated Europe centuries earlier. Where the Black Death killed in days, the white plague killed slowly, sometimes over months or years, draining a person’s weight, energy, and color until they were unrecognizable.
The romantic era of the 18th and 19th centuries actually glamorized this pallor. Pale skin became fashionable in European culture, and tuberculosis was sometimes called the “poet’s disease” because so many writers and artists suffered from it. John Keats, the Brontë sisters, Frédéric Chopin, and Anton Chekhov all died of tuberculosis. The flushed cheeks and thin frame of a tuberculosis patient were paradoxically seen as markers of sensitivity and creative genius.
What Tuberculosis Does to the Body
Tuberculosis is caused by a bacterium that spreads through the air when someone with an active lung infection coughs, speaks, or breathes. When inhaled, the bacteria settle deep in the lungs, where immune cells called macrophages attempt to destroy them. In many cases, this first line of defense succeeds. But the tuberculosis bacterium has an unusual trick: it can break out of the compartment where immune cells trap it, escaping into the cell’s interior where it can survive and multiply in a protected environment.
If the bacteria overcome the initial immune response, they replicate rapidly inside the lungs over several weeks. The immune system eventually responds by walling off the bacteria inside dense clusters of immune cells called granulomas, small lumps of tissue that can contain the infection but don’t always eliminate it. In some cases, the bacteria spread through the bloodstream to other organs, including the kidneys, spine, and brain.
The hallmark symptoms that gave the disease its old name “consumption” are severe weight loss, chronic cough (often with blood), night sweats, fever, and fatigue. Modern studies confirm that about 87.5% of tuberculosis patients experience unintentional weight loss. The infection increases the body’s energy demands while simultaneously killing appetite, creating a devastating cycle of malnutrition that made the disease so visually striking in an era before effective treatment.
Latent Versus Active Infection
Not everyone who breathes in tuberculosis bacteria gets sick. In most healthy people, the immune system contains the bacteria in those granuloma clusters, keeping them dormant. This is called latent tuberculosis infection. A person with latent infection has no symptoms, feels fine, and cannot spread the disease to others.
Without treatment, about 5% to 10% of people with latent infection will eventually develop active tuberculosis disease at some point in their lives. Certain conditions dramatically increase that risk: HIV infection, diabetes, kidney failure, certain cancers, and any therapy that suppresses the immune system. Children under five and people who were infected within the past two years are also at higher risk. In the United States, progression from untreated latent infection accounts for roughly 80% of active tuberculosis cases, which is why screening and treating latent infection remains a major public health priority.
How It Was Treated Before Antibiotics
For most of history, there was no cure for tuberculosis. The primary strategy from the late 1800s through the mid-1900s was the sanatorium, a residential facility where patients were isolated from the general population and given rest, sunlight, clean mountain air, and enormous amounts of food (some facilities prescribed 6,000 calories a day, believing it would help patients regain lost weight). Doctors observed that the disease seemed less common at higher altitudes, and sanatorium towns like Davos, Switzerland, perched at 1,560 meters above sea level, became famous destinations for tuberculosis patients.
Life in a sanatorium could stretch on for months or years. Thomas Mann captured this reality in his 1924 novel “The Magic Mountain,” where patients at a Swiss sanatorium measure time in months and spend their days resting horizontally on balconies. These facilities were as much about containment as treatment. At a time when no drug could kill the bacterium, isolating patients in dedicated facilities was the only practical way to slow the spread.
The Antibiotic Breakthrough
The first effective drug against tuberculosis, streptomycin, was announced in 1945. For the first time in history, doctors could actually kill the bacterium rather than simply hoping a patient’s immune system would contain it. However, the bacteria quickly developed resistance to streptomycin when it was used alone, and researchers soon learned that tuberculosis required treatment with multiple drugs simultaneously to prevent resistance from emerging.
Modern tuberculosis treatment typically involves a combination of antibiotics taken over six to nine months. The long treatment duration is necessary because the bacteria grow slowly and can hide inside immune cells, making them difficult to eliminate completely. Patients usually start feeling better within a few weeks, but stopping treatment early is one of the main drivers of drug resistance.
Drug-Resistant Strains
One of the most serious challenges in fighting tuberculosis today is the emergence of strains that no longer respond to standard medications. Multidrug-resistant tuberculosis (MDR-TB) resists at least the two most powerful first-line antibiotics. Extensively drug-resistant tuberculosis (XDR-TB) goes further, resisting additional backup drugs as well. These resistant strains are harder to treat, require longer and more toxic drug regimens, and have lower cure rates. Drug resistance is confirmed through laboratory testing, and its emergence is closely tied to incomplete treatment courses and inconsistent access to medication.
Tuberculosis Today
Despite being curable for nearly 80 years, tuberculosis remains one of the world’s leading infectious killers. In 2024, an estimated 10.7 million people fell ill with tuberculosis worldwide, and 1.23 million died from the disease (including 150,000 people who were also living with HIV). Men account for the majority of cases at 5.8 million, followed by 3.7 million women and 1.2 million children.
The disease disproportionately affects low- and middle-income countries, particularly in sub-Saharan Africa and Southeast Asia, where crowded living conditions, HIV prevalence, and limited healthcare access create ideal conditions for transmission. In wealthier nations, tuberculosis cases are far less common but still occur, often among immigrants, people experiencing homelessness, and those with compromised immune systems. The white plague may have a historical name, but the disease it describes is far from history.